|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online January 23, 2008
doi: 10.1242/10.1242/jcs.022459
Commentary |
1 Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2 Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
3 Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
4 Department of Genetics, Case Western Reserve University School of Medicine, Cleveland, OH, USA
5 CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
* Author for correspondence (e-mail: engc{at}ccf.org)
Accepted 15 November 2007
PTEN encodes a major tumor-suppressor protein that is a dual-specificity phosphatase. Inactivation of PTEN has been shown to be involved in heritable and sporadic cancers. Mutation or deletion of PTEN, historically the most commonly identified mechanisms of inactivation of tumor suppressors, is found only in the minority of sporadic non-cultured primary cancers, which indicates that there might be other, novel mechanisms of inactivation. Despite the absence of a classic nuclear localization signal, PTEN enters the nucleus by several mechanisms, including simple diffusion, active shuttling, cytoplasmic-localization-signal-dependent export and monoubiquitylation-dependent import. Cytoplasmic PTEN has a well-known role as a negative regulator of the PI3K/AKT pathway; however, it is becoming clear that cytosolic PTEN is not the same as nuclear PTEN. Nuclear PTEN plays a role in chromosome stability, DNA repair, cell cycle arrest and cellular stability. The balance between these functions is an important factor in determining whether a cell remains benign or becomes neoplastic.
Key words: PTEN, Nuclear, Subcellular localization, Cowden, PHTS, Bifurcation
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Platt, C. D. Hurst, C. F. Taylor, W. M. Gregory, P. Harnden, and M. A. Knowles Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer Clin. Cancer Res., October 1, 2009; 15(19): 6008 - 6017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ressel, F. Millanta, E. Caleri, V. M. Innocenti, and A. Poli Reduced PTEN Protein Expression and Its Prognostic Implications in Canine and Feline Mammary Tumors Vet. Pathol., September 1, 2009; 46(5): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Huang, S.-F. Huang, I-H. Chen, C.-T. Liao, H.-M. Wang, and L.-L. Hsieh Methylation of RASSF1A, RASSF2A, and HIN-1 Is Associated with Poor Outcome after Radiotherapy, but not Surgery, in Oral Squamous Cell Carcinoma Clin. Cancer Res., June 15, 2009; 15(12): 4174 - 4180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y. Oudit and J. M. Penninger Cardiac regulation by phosphoinositide 3-kinases and PTEN Cardiovasc Res, May 1, 2009; 82(2): 250 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Samuelson, C. Hedberg, S. Nilsson, and A. Behboudi Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats Endocr. Relat. Cancer, March 1, 2009; 16(1): 99 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gambetta, M. K. Al-Ahdab, M. N. Ilbawi, N. Hassaniya, and M. Gupta Transcription repression and blocks in cell cycle progression in hypoplastic left heart syndrome Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2268 - H2275. [Abstract] [Full Text] [PDF]
|
|
